A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Jaktinib in Patients With Moderate-to-Severe Plaque Psoriasis
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Gecaxitinib hydrochloride (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 04 Mar 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 04 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 04 Mar 2024 Status changed from recruiting to active, no longer recruiting.